Precigen, Inc. is highlighted as one of the 15 Best Biotech Penny Stocks to Invest in Right Now. The company recently achieved a major milestone with the first FDA-approved therapy for recurrent respiratory papillomatosis. In early September 2025, Precigen secured up to $125 million to support the commercialization of this therapy and explore other indications. Despite positive developments, the company faces challenges with share dilution and ongoing operating losses.

For investors interested in AI stocks, there are options with greater upside potential and less downside risk than Precigen. While PGEN shows promise as an investment, other AI stocks may offer better opportunities. Check out our free report on the best short-term AI stock for more information.

This article also discusses 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Now for those looking for investment opportunities. No disclosure is provided in this news piece.

Read more at Yahoo Finance: Precigen, Inc. (PGEN) Secures $125M to Accelerate PAPZIMEOS Commercialization